Literature DB >> 27739611

Efficient Generation of β-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells from Patients with Sickle Cell Disease.

Naoya Uchida1, Juan J Haro-Mora1, Atsushi Fujita1, Duck-Yeon Lee2, Thomas Winkler3, Matthew M Hsieh1, John F Tisdale1.   

Abstract

Human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells represent an ideal source for in vitro modeling of erythropoiesis and a potential alternative source for red blood cell transfusions. However, iPS cell-derived erythroid cells predominantly produce ε- and γ-globin without β-globin production. We recently demonstrated that ES cell-derived sacs (ES sacs), known to express hemangioblast markers, allow for efficient erythroid cell generation with β-globin production. In this study, we generated several iPS cell lines derived from bone marrow stromal cells (MSCs) and peripheral blood erythroid progenitors (EPs) from sickle cell disease patients, and evaluated hematopoietic stem/progenitor cell (HSPC) generation after iPS sac induction as well as subsequent erythroid differentiation. MSC-derived iPS sacs yielded greater amounts of immature hematopoietic progenitors (VEGFR2 + GPA-), definitive HSPCs (CD34 + CD45+), and megakaryoerythroid progenitors (GPA + CD41a+), as compared to EP-derived iPS sacs. Erythroid differentiation from MSC-derived iPS sacs resulted in greater amounts of erythroid cells (GPA+) and higher β-globin (and βS-globin) expression, comparable to ES sac-derived cells. These data demonstrate that human MSC-derived iPS sacs allow for more efficient erythroid cell generation with higher β-globin production, likely due to heightened emergence of immature progenitors. Our findings should be important for iPS cell-derived erythroid cell generation. Stem Cells 2017;35:586-596.
© 2016 AlphaMed Press.

Entities:  

Keywords:  Erythroid differentiation; Hemogenic endothelium; Pluripotent stem cells; Primitive and definitive hematopoiesis

Mesh:

Substances:

Year:  2016        PMID: 27739611      PMCID: PMC5330841          DOI: 10.1002/stem.2517

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  54 in total

1.  Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.

Authors:  Jizhong Zou; Prashant Mali; Xiaosong Huang; Sarah N Dowey; Linzhao Cheng
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

2.  In vitro generation of lymphohematopoietic cells from endothelial cells purified from murine embryos.

Authors:  S I Nishikawa; S Nishikawa; H Kawamoto; H Yoshida; M Kizumoto; H Kataoka; Y Katsura
Journal:  Immunity       Date:  1998-06       Impact factor: 31.745

3.  Definitive hematopoiesis is autonomously initiated by the AGM region.

Authors:  A Medvinsky; E Dzierzak
Journal:  Cell       Date:  1996-09-20       Impact factor: 41.582

4.  Transgene-free iPSCs generated from small volume peripheral blood nonmobilized CD34+ cells.

Authors:  Randall K Merling; Colin L Sweeney; Uimook Choi; Suk See De Ravin; Timothy G Myers; Francisco Otaizo-Carrasquero; Jason Pan; Gilda Linton; Lifeng Chen; Sherry Koontz; Narda L Theobald; Harry L Malech
Journal:  Blood       Date:  2013-02-05       Impact factor: 22.113

5.  Inducing definitive hematopoiesis in a dish.

Authors:  Mervin C Yoder
Journal:  Nat Biotechnol       Date:  2014-06       Impact factor: 54.908

6.  Differential expression of KDR/VEGFR-2 and CD34 during mesoderm development of the early human embryo.

Authors:  F Cortés; C Debacker; B Péault; M C Labastie
Journal:  Mech Dev       Date:  1999-05       Impact factor: 1.882

7.  Reprogramming of human somatic cells to pluripotency with defined factors.

Authors:  In-Hyun Park; Rui Zhao; Jason A West; Akiko Yabuuchi; Hongguang Huo; Tan A Ince; Paul H Lerou; M William Lensch; George Q Daley
Journal:  Nature       Date:  2007-12-23       Impact factor: 49.962

Review 8.  Blood transfusion risks in the intensive care unit.

Authors:  Mercy Kuriyan; Jeffrey L Carson
Journal:  Crit Care Clin       Date:  2004-04       Impact factor: 3.598

9.  Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures.

Authors:  Bin-Kuan Chou; Prashant Mali; Xiaosong Huang; Zhaohui Ye; Sarah N Dowey; Linda Ms Resar; Chunlin Zou; Y Alex Zhang; Jay Tong; Linzhao Cheng
Journal:  Cell Res       Date:  2011-01-18       Impact factor: 25.617

10.  Wnt signaling controls the specification of definitive and primitive hematopoiesis from human pluripotent stem cells.

Authors:  Christopher M Sturgeon; Andrea Ditadi; Geneve Awong; Marion Kennedy; Gordon Keller
Journal:  Nat Biotechnol       Date:  2014-05-18       Impact factor: 54.908

View more
  19 in total

1.  Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients.

Authors:  Naoya Uchida; Atsushi Fujita; Matthew M Hsieh; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Robert E Donahue; John F Tisdale
Journal:  Hum Gene Ther Clin Dev       Date:  2017-04-17       Impact factor: 5.032

Review 2.  Stem cell manipulation, gene therapy and the risk of cancer stem cell emergence.

Authors:  Flora Clément; Elodie Grockowiak; Florence Zylbersztejn; Gaëlle Fossard; Stéphanie Gobert; Véronique Maguer-Satta
Journal:  Stem Cell Investig       Date:  2017-07-25

Review 3.  Induced pluripotent stem cells in disease modelling and drug discovery.

Authors:  R Grant Rowe; George Q Daley
Journal:  Nat Rev Genet       Date:  2019-07       Impact factor: 53.242

Review 4.  Induced Pluripotent Stem Cell-Derived Red Blood Cells and Platelet Concentrates: From Bench to Bedside.

Authors:  Daniele Focosi; Giovanni Amabile
Journal:  Cells       Date:  2017-12-27       Impact factor: 6.600

Review 5.  Recent Updates on Induced Pluripotent Stem Cells in Hematological Disorders.

Authors:  Methichit Wattanapanitch
Journal:  Stem Cells Int       Date:  2019-05-02       Impact factor: 5.443

6.  Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders.

Authors:  Naoya Uchida; Matthew M Hsieh; Lydia Raines; Juan J Haro-Mora; Selami Demirci; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Robert E Donahue; John F Tisdale
Journal:  Nat Commun       Date:  2019-10-02       Impact factor: 14.919

7.  Biallelic correction of sickle cell disease-derived induced pluripotent stem cells (iPSCs) confirmed at the protein level through serum-free iPS-sac/erythroid differentiation.

Authors:  Juan J Haro-Mora; Naoya Uchida; Selami Demirci; Qi Wang; Jizhong Zou; John F Tisdale
Journal:  Stem Cells Transl Med       Date:  2020-02-07       Impact factor: 6.940

Review 8.  A Preview of Selected Articles.

Authors:  Stuart P Atkinson
Journal:  Stem Cells Transl Med       Date:  2020-05       Impact factor: 6.940

9.  βT87Q-Globin Gene Therapy Reduces Sickle Hemoglobin Production, Allowing for Ex Vivo Anti-sickling Activity in Human Erythroid Cells.

Authors:  Selami Demirci; Bjorg Gudmundsdottir; Quan Li; Juan J Haro-Mora; Tina Nassehi; Claire Drysdale; Morgan Yapundich; Jackson Gamer; Fayaz Seifuddin; John F Tisdale; Naoya Uchida
Journal:  Mol Ther Methods Clin Dev       Date:  2020-04-18       Impact factor: 6.698

10.  Serum-free Erythroid Differentiation for Efficient Genetic Modification and High-Level Adult Hemoglobin Production.

Authors:  Naoya Uchida; Selami Demirci; Juan J Haro-Mora; Atsushi Fujita; Lydia N Raines; Matthew M Hsieh; John F Tisdale
Journal:  Mol Ther Methods Clin Dev       Date:  2018-03-22       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.